Quinapril: adverse event reports filed with FDA

1,231

reports as suspect product

0% of all reports · about 57 a year

12

reports, 12 months to June 2026

23 in the 12 months before

59.7%

marked serious by the reporter

83.4% across the class

5%

record death among outcomes, as reported

61 reports · not verified by FDA

Reports by month, five years

Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

By year received

2026 covers reports received through June 2026 only.

Reactions recorded in the reports

share of Quinapril reports recording the termmedian drug in angiotensin converting enzyme inhibitor

1. Falla fall17.7%218
2. Recalled product administered16.4%202
3. No adverse eventno adverse event was reported15%185
4. Cognitive disorderproblems with thinking or memory14.5%178
5. Orthostatic hypotension14.3%176
6. Hypotensionlow blood pressure14.2%175
7. Balance disorderproblems with balance13.5%166
8. Constipationconstipation13.5%166
9. Sedationdrowsiness from a medicine12.8%158
10. Sedation complication12.1%149
11. Painpain, site not specified11.9%147
12. Toxicity to various agentspoisoning or toxic effect of one or more substances11.9%146
13. Depressed level of consciousness11.8%145
14. Mobility decreasedreduced ability to move about11.8%145
15. Blood calcium decreased11.1%137
16. Creatinine renal clearance decreased11.1%137
17. Dyspnoeashortness of breath9.2%113
18. Drug ineffectivethe medicine did not work as expected9.1%112
19. Drug interactionan interaction between medicines6.4%79
20. Coughcough5.3%65
21. Drug hypersensitivityan allergic-type reaction to a medicine5.2%64
22. Malaisegeneral feeling of being unwell4.5%56
23. Angioedemadeep swelling of skin or mucous membranes4.1%50
24. Product substitution issuea problem after switching products3.8%47
25. Blood pressure increaseda raised blood pressure reading3.5%43
26. Overdosea dose above the recommended amount3.5%43
27. Product use in unapproved indicationused for a purpose not on the label3.5%43
28. Chest painchest pain3.4%42
29. Renal function test abnormal3.3%41
30. Multiple drug therapy3.2%39

Top 30 of 275 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the median share across the 13 drugs in the angiotensin converting enzyme inhibitor class; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Outcomes recorded

Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 102,327 reports in the class. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."

Patients and reporters

Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 58.9% of reports give the United States as the country of the event or reporter.

Reason for use recorded

The indication field is filled in by the reporter and is often blank; shares are of all 1,231 reports.

Drugs most often listed in the same reports

Other products listed in reports where Quinapril is a suspect product, whatever their own role. Co-listing means the two were recorded together; it says nothing about either product's part in the event. Only the 2,500 most-reported names are counted here.

In context

Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Other drugs in the angiotensin converting enzyme inhibitor class

Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." A brand and its generic are separate rows because reporters name them separately.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Quinapril as a suspect or interacting product; reports listing it only as a concomitant medication (5,642) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.